TransMedics Group, Inc. (TMDX)

Market Cap	2.85B
Revenue (ttm)	241.62M
Net Income (ttm)	-25.03M
Shares Out	32.72M
EPS (ttm)	-0.77
PE Ratio	n/a
Forward PE	250.00
Dividend	n/a
Ex-Dividend Date	n/a

Volume	685,795
Open	88.80
Previous Close	87.86
Day's Range	85.84 - 90.15
52-Week Range	36.42 - 99.63
Beta	1.98
Analysts	Buy
Price Target	95.14 (+9.06%)
Earnings Date	Apr 30, 2024

About TMDX

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung trans...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: May 2, 2019
• Employees: 584
• Stock Exchange: NASDAQ
• Ticker Symbol: TMDX

Financial Performance

In 2023, TMDX's revenue was $241.62 million, an increase of 158.53% compared to the previous year's $93.46 million. Losses were -$25.03 million, -30.92% less than in 2022.

Analyst Forecast

According to 7 analysts, the average rating for TMDX stock is "Buy." The 12-month stock price forecast is $95.14, which is an increase of 9.06% from the latest price.

Price Target

$95.14

(9.06% upside)

Analyst Consensus: Buy